BeiGene To Become First Tri-Listed Biotech Amid Offer Price Concerns

 
• By Dexter Jie Yan

Nasdaq, Hong Kong and soon Shanghai, major Chinese firm BeiGene will be listed on three stock markets globally. But the high offer price of its imminent debut on China's STAR Market has raised concern among some investments and involved the use of a rare mechanism in the country.

Stock Exchange STAR Market
BeiGene's Shanghai IPO price draws investor concerns in China. • Source: Alamy

More from China

More from Focus On Asia